Selvita Completes $ 5.5 Million Private Placement


Krakow –Polish drug discovery company Selvita has entered into definitive agreements with investors in Poland to sell, in a private placement, 2.7 million shares of its stock at a price of PLN 5.5 per share, resulting in gross proceeds to the company of PLN 14.85 million ($5.5 million). The capitalisation of the company after the issue will be around $21 million. Selvita expects its stock to be listed on the Warsaw Stock Exchange NewConnect market in June 2011. Proceeds from the financing will be used for the ongoing pre-clinical development of Selvita’s drug candidates including the first in class compounds: SEL24 (Pim kinase inhibitors in oncology), SEL120 (anti-mitotic agent with a novel mechanism of action) and SEL113 (oncology and auto-immune disorders). The company will also expand its lab space for outsourcing of drug discovery projects which is the second pillar of Selvita’s business model. The majority of the company shares will continue to be controlled by its management. The largest new shareholder will be Dr. Tadeusz Wesolowski, the founder of Prosper, one of the largest pharmaceutical distributors in Poland who will join Selvita’s supervisory board as its Vice President. The company’s turnover amounted to PLN3.1 mln in 2009 with PLN3 million net loss. Forecasts for this year are not reported. Sel24 is a group of compounds which are specific inhibitors of Pim-1 kinase, which are in the downstream signalling pathways of several oncogenes including FLT3-ITD, Bcr-Abl or Jak2 and play important role in oncogenic transformation. Pim-1 kinases are also markers for poor prognosis. The lead compound, SEL24-1 has shown antitumour activity in vivo in 4 different mouse xenograft models of estrogen resistant breast cancer cells, hematopoietic cancers and other solid tumours at an IC of less than 10nM. Moreover, preliminary results show that the company’s lead compound SEL24-1 is safe and non-toxic in non-neoplastic cells and tissues in vitro and in vivo.
First-in-human application is planned for 2012. Furthermore Selvita is developing SEL103 against Alzheimer’s disease in partnership with the Finish Orion Corporation.



Krakow – Polish drug discovery specialist Selvita S.A. is to carry out virtual compound screening for a protein target provided by the Branford-based Institutes for Pharmaceutical Discovery (IPD) in the US. Selvita said the...



Warsaw – Poland’s policy concerning genetically modified organisms (GMOs) has been challenged by the European Commission. In mid-March, the Commission sued Poland at the European Court of Justice (ECJ) for establishing a ban on...



Szczecin/Greifswald – In Greifswald, the consensus in mid-March at the “Life Science for Health Economy – Chances and Challenges in Polish-German Cooperation” meeting was that the life sciences would benefit remarkably from...



Warsaw – Polish drugmaker Bioton S.A. and Iceland-based generics firm Actavis Group ptc announced in January that they are entering into a marketing and distribution collaboration agreement for Bioton’s insulins and insulin...



Warsaw – Merck, Sharp & Dome Polska is to expand its clinical research in the country. The company announced it is investing about US$ 50m in the creation of a data management centre where data from clinical trials conducted in...



Warsaw – Polish Agriculture Minister Marek Sawicki has sharply criticised the European Commission’s proposal to let EU member states decide on their own whether or not to plant genetically mod­i­fied crops. “This proposal is not...



Krakow – Polish drug developer Selvita sp. z o.o. and Finnish drug and diagnostic firm Orion Corporation (Espoo) have entered into a global collaboration to jointly develop and commercialise Selvita’s oral compound SEL103 as a...



Warsaw – While industrial biotechnology companies such as Royal DSM or Novozymes have welcomed new EU climate goals, believing they will provide a kickstart for a bio-based economy, eastern European countries like Bulgaria, the...



Kraków/ Espoo – Finland’s Orion Corp and Polish drugmaker Selvita have agreed to collaborate on research and development of Selvita’s oral Alzheimer compound SEL103 program in multiple cognitive disorder indications. According to...



Warsaw – Polish biotech firm Bioton SA wants to expand its business to Asia. At the end of April, the producer of recombinant insulin announced that it plans to issue convertible bonds worth EUR26m to fund an expansion of its...

Displaying results 11 to 20 out of 108

< Previous 11-20 Next >

© 2007-2015 BIOCOM



LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...

Product of the week



All Events


Frankfurt am Main (DE)


Stock list

All quotes


  • MEDIGENE8.76 EUR2.10%
  • EPIGENOMICS5.31 EUR1.53%
  • MOLOGEN4.99 EUR1.42%


  • SARTORIUS160.55 EUR-5.36%
  • WILEX4.05 EUR-3.57%


  • 4SC4.66 EUR258.5%
  • SYNGENTA421.00 CHF28.8%
  • BASILEA134.80 CHF18.0%


  • CYTOS0.62 CHF-39.2%
  • MEDIGENE8.76 EUR-28.0%
  • CO.DON2.85 EUR-17.4%


  • WILEX4.05 EUR406.3%
  • 4SC4.66 EUR323.6%
  • FORMYCON27.20 EUR294.2%


  • MOLOGEN4.99 EUR-54.0%
  • BIOFRONTERA2.30 EUR-24.6%
  • THERAMETRICS0.07 CHF-22.2%

No liability assumed, Date: 27.05.2015

Current issue

All issues